Every Form 4 that Jade Biosciences, Inc. (JBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow JBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JBIO filings page.
Jade Biosciences, Inc. director Mark Eisner reported receiving a stock option grant that gives him the right to buy 47,675 shares of common stock at an exercise price of $21.81 per share. All 47,675 option shares were reported as held directly after the grant.
The option expires on June 24, 2036. According to the footnote, 1/36 of the total option shares vest monthly after the grant date, as long as Eisner continues to provide service to the company on each vesting date. This structure turns the award into ongoing, service-based compensation rather than an immediate, fully vested position.
Jade Biosciences director Christopher W. Cain received a grant of stock options covering 34,843 shares of common stock at an exercise price of $15.22 per share. The option vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to his continued service.
Under an arrangement with Fairmount Funds Management LLC, Cain holds this option for one or more Fairmount investment funds and must turn over any net cash or stock to Fairmount for those funds. Both Cain and Fairmount disclaim beneficial ownership of the option and underlying shares.
DOBMEIER ERIC reported acquisition or exercise transactions in this Form 4 filing.
Jade Biosciences, Inc. director Eric Dobmeier received a stock option grant covering 34,843 shares of common stock. The option has a strike price of $15.22 per share and expires on June 8, 2036. It vests in full on June 9, 2027 or at the next annual stockholder meeting, subject to his continued service.
Jade Biosciences director Klein Lawrence Otto received a grant of stock options covering 34,843 shares of common stock. These options have an exercise price of $15.22 per share and expire on June 8, 2036. The award vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to his continued service. Following this compensation grant, he holds 34,843 derivative securities directly.
Jade Biosciences director Erin Lavelle received a stock option grant covering 34,843 shares of common stock. The option has an exercise price of $15.22 per share and expires on June 8, 2036. It vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to her continued service.
Jade Biosciences, Inc. reported a compensation-related insider transaction involving a stock option grant. Director Tomas Kiselak received an option covering 34,843 shares of common stock at an exercise price of $15.22 per share, with no cash paid for the grant itself.
The option vests in full on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to Kiselak’s continued service to the company. The option expires on June 8, 2036, giving a long-dated right to purchase shares once vested.
A footnote explains that Kiselak holds this option for one or more investment vehicles managed by Fairmount Funds Management LLC, and he must turn over any net cash or stock from the option to Fairmount for the benefit of the relevant Fairmount fund. Fairmount, Peter Harwin, and Kiselak each disclaim beneficial ownership of the securities except to the extent of any pecuniary interest.
Jade Biosciences Chief Financial Officer Bradford D. Dahms received new equity awards on February 12, 2026. He was granted 37,813 shares of common stock in the form of restricted stock units at no cash cost, each representing a right to one share.
These RSUs vest in four equal installments on each of the first four anniversaries of February 15, 2026, contingent on continued service. Dahms was also granted stock options for 226,875 shares of common stock with a $14.81 exercise price, granted at no cost.
One quarter of the options vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, also subject to his continued service. All reported holdings are shown as directly owned.
Jade Biosciences, Inc. granted equity awards to Chief Legal Officer and Corporate Secretary Elizabeth Balta. On February 12, 2026, she received 28,125 shares of common stock in the form of restricted stock units at $0 per share and a stock option for 168,750 shares with a $14.81 exercise price.
The RSUs vest in four equal parts on each of the first four anniversaries of February 15, 2026, if she remains in service. The option vests 25% on February 15, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, also contingent on continued service.
Frohlich Tom reported acquisition or exercise transactions in a Form 4 filing for JBIO. The filing lists transactions totaling 551,250 shares. Following the reported transactions, holdings were 472,500 shares.
Jade Biosciences, Inc. officer Andrew James King reported equity compensation awards that increase his stake in the company. On February 12, 2026, he received 41,250 shares of common stock as a grant priced at $0 per share, bringing his directly owned common shares to 386,113.
He was also granted a stock option for 247,500 shares at an exercise price of $14.81 per share, expiring on February 11, 2036, with 247,500 derivative securities owned after the grant. The 41,250-share common stock grant is in the form of restricted stock units, vesting in four equal annual installments starting on February 15, 2026. The option vests 25% on February 15, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, all subject to his continued service.
Insiders and affiliated funds purchased equity in Jade Biosciences (JBIO). On 10/06/2025, affiliated investors acquired 1,333,126 shares of common stock at $9.14 per share and received 855,047 pre-funded warrants exercisable into the same number of shares (exercise price $0.0001); the underlying common shares for the warrants are tied to an effective price of $9.1399. After the transactions, the reported beneficial ownership stakes include 1,897,677 shares attributed indirectly to Fairmount Healthcare Fund II L.P. and 2,655,817 shares indirectly attributed to Fairmount Healthcare Co-Invest IV L.P.
The filing notes the securities were purchased in a private placement and relies on Rule 16b-3(d)(1) exemption. Fairmount Funds Management LLC is the manager for the two funds, and Tomas Kiselak and Peter Harwin are identified as managers; they disclaim beneficial ownership except for pecuniary interests. The pre-funded warrants have no expiration and include a 9.99% beneficial ownership cap on exercise.